BiologicsFinancial

INFUSE SALES LEADING MEDTRONIC SPINE TO HEALTH

Walter Eisner • Thu, November 20th, 2014

Medtronic Inc.’s spine’s most recent quarter’s sales beat Wall Street expectations. Most surprisingly, Infuse is credited with causing the surprise.

Yes, you read that right. Biologic sales for Medtronic’s second quarter rose 9% on a reported basis while Core Spine and Interventional Spine, which consists of the company’s balloon kyphoplasty product line slipped 1% and 6%, respectively. Management said the company’s kyphoplasty sales were affected by a product supply issue related to the cement delivery system.

 

Source: Medtronic, Inc.

Underlying Stable BMP Demand

BMP (bone morphogenetic protein—Infuse) sales of a $120 million, according to Medtronic’s CFO Gary Ellis, grew with stable underlying demand. “While sales of BMP bounced round a bit, we do believe we have turned the corner and would expect BMP sales growth to be slightly positive going forward.”

READ THE REST AT RYORTHO

Tags

Josh Sandberg

Josh Sandberg is the President of Ortho Sales Partners and Partner for The De Angelis Group. He also serves as Co-Founder and Editor of OrthoSpineNews.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Close